European regulators initially said in July that the drug's benefits did not outweigh its risks. View on euronews ...

Michael Yee has given his Buy rating due to a combination of factors including the recent positive developments regarding Biogen’s Alzheimer’s drug, Leqembi, in the European market. The European ...

A key regulatory committee sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market.

After re-examining its initial opinion, EMA’s human medicines committee, or CHMP, has recommended granting a marketing authorisation to Leqembi for treating mild cognitive impairment or mild dementia ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

Now, in seeking approval for Leqembi as a maintenance treatment, Eisai is proposing that patients could receive a more convenient form of the drug after completing an initial regimen of biweekly ...

The adjustment comes after a reassessment of the anticipated performance of Biogen's Alzheimer's treatment, Leqembi. The launch of Leqembi has not met the expectations set by analysts, leading to ...

The adjustment comes after a reassessment of the anticipated performance of Biogen's Alzheimer's treatment, Leqembi. The launch of Leqembi has not met the expectations set by analysts, leading to ...

Eisai Co (ESAIY) and Biogen Inc. (BIIB) announced that the latest findings for lecanemab-irmb, an anti-amyloid beta protofibril* antibody for the treatment of early Alzheimer’s disease, were ...

STOCKHOLM, Oct. 30, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the third quarter 2024 ...

The company also raised its full-year profit guidance. Sales of its breakthrough Alzheimer's drug, Leqembi, along with new rare disease and depression treatments, helped offset a year-over-year ...